Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 6, 2012, Pages 1258-1271

  Korhonen, P ^a   Zuber, E ^b   Branson, M ^b   Hollaender, N ^b   Yateman, N ^c   Katiskalahti, T ^a   Lebwohl, D ^b   Haas, T ^b  

^a StatFinn Oy   (Finland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SDE Services AG   (Switzerland)

Author keywords

Everolimus; Rank preserving accelerated failure time model; Treatment crossover

Indexed keywords

EVEROLIMUS; PLACEBO;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RANK PRESERVING STRUCTURAL FAILURE TIME MODEL; STATISTICAL MODEL; SURVIVAL TIME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MODELS, STATISTICAL; MODELS, STRUCTURAL; NEOPLASM METASTASIS; SIROLIMUS; TREATMENT FAILURE;

EID: 84869744113     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2011.592233     Document Type: Article

References (21)

1. Amato, R. J., Misellati, A., Khan, M., Chiang, S. (2006). A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology 24(18 suppl): abstract 4530.
2. Atkins, M. B., Hidalgo, M., Stadler, W. M., et al. (2004). R and omized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 22:909-918. (Pubitemid 41103603)
3. Cain, L. E., Cole, S. R. (2009). Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of r and omized highly active antiretroviral therapy on incident AIDS or death. Statistics in Medicine 28:1725-1738.
4. Cole, S. R., Chu, H. (2005). Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemporary Clinical Trials 26:300-310. (Pubitemid 40725994)
5. Demetri, G. D., Huang, X., Garrett, C. R., et al. (2008). Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. Journal of Clinical Oncology 26(May 20 suppl. ): abstr. 10524.
6. FDA Will Revisit Appropriate Use Of PFS Endpoints at Advisory Committee. (2009). Health News Daily, September.
7. Fleming, T., Harrington, D. (1981). A class of hypothesis tests for one and two samples of censored survival data. Communications in Statisitics 10:763-794.
8. Fleming, T. R., Rothmann, M. D., Hong, L. L. (2009). Issues in using progression-free survival when evaluating oncology products. Journal of Clinical Oncology 27:2874-2880.
9. Food and Drug Administration. (2007). Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Washington, DC: U. S. Department of Health and Human Services.
10. Hernán, M. A., Cole, S. R., Margolick, J., Cohen, M., Robins, J. M. (2005). Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Safety 14:477-491. (Pubitemid 40990743)
11. Holl and , P. (1986). Statistics and causal inference. Journal of the American Statistical Association 81:945-961.
12. Korhonen, P., Laird, N., Palmgren, J. (1999). Correcting for non-compliance in r and omised trials: An application to the ATBC study. Statistics in Medicine 18:2879-2897. (Pubitemid 29500029)
13. Motzer, R. J., Escudier, B., Oudard, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, r and omised, placebo-controlled Phase III trial. Lancet 372:449-456.
14. Motzer, R., Escudier, B., Oudard, S., et al. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265.
15. Robins, J. M. (1998a). Structural nested failure time models. In: And ersen, P. K., Keiding, N., section eds. Survival Analysis. In: Armitage, P., Colton, C., eds. The Encyclopedia of Biostatistics. Chichester, UK: John Wiley and Sons, pp. 4372-4389.
16. Robins, J. M. (1998b). Marginal structural models. In: 1997 Proceedings of the Section on Bayesian Statistical Science. Alex and ria, VA: American Statistical Association, pp. 1-10.
17. Robins, J. M. (1999). Marginal structural models versus structural nested models as tools for causal inference. In: Halloran, E., Berry, D., eds. Statistical Models in Epidemiology: The Environment and Clinical Trials. New York, NY: Springer-Verlag, pp. 95-134.
18. Robins, J. M., Hernán, M. A., Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. Epidemiology 11:550-560. (Pubitemid 30660034)
19. Robins, J. M., Tsiatis, A. A. (1991). Correcting for non-compliance in r and omized trials using rank preserving structural failuretime models. Communications in Statistics 20:2609-2631.
20. Rubin, D. B. (1978). Bayesian inference for causal effects: The role of r and omization. Annals of Statistics 6:34-58.
21. White, I. R., Babiker, A. G., Walker, S., Darbyshire, J. H. (1999). R and omization-based methods for correcting for treatment changes: Examples from the Concorde trial. Statistics in Medicine 18:2617-2634. (Pubitemid 29465600)